In vitro inhibition of enterobacteria-reactive CD4+CD25- T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027

European Journal of Pharmacology

Volumn 586, Issue 1-3, 2008, Pages 313-321

  Mangano, Katia ^a   Sardesai, Niranjan ^b   D'Alcamo, Maria ^a   Libra, Massimo ^a   Malaguarnera, Lucia ^a   Donia, Marco ^a   Bendtzen, Klaus ^c   Meroni, Pierluigi ^d   Nicoletti, Ferdinando ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b VGX Pharmaceuticals Inc   (United States)

^c Rigshospitalet   (Denmark)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Cytokines; Immunotherapy; Inflammatory bowel diseases; Nuclear factor B VGX 1027

Indexed keywords

3 PHENYL 4,5 DIHYDRO 5 ISOXASOLE ACETIC ACID; BACTERIAL ANTIGEN; DEXAMETHASONE; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; SULFONIC ACID DERIVATIVE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; VGX 1027;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENTEROBACTERIACEAE; FEMALE; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ACETIC ACIDS; ANIMALS; ANTIGEN-PRESENTING CELLS; BODY WEIGHT; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELL SEPARATION; COLITIS; CYTOKINES; DIARRHEA; ENTEROBACTERIACEAE; FEMALE; GASTROINTESTINAL HEMORRHAGE; IMMUNOLOGIC FACTORS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTESTINAL MUCOSA; MICE; MICE, INBRED BALB C; OXAZOLES; PEROXIDASE; TRANSCRIPTION FACTOR RELA;

EID: 43749093434     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.02.017     Document Type: Article

References (27)

1. Brines J., Reimann J., Nissen M.H., and Claesson M.H. Enteric bacterial antigens activate CD4+ T-cells from scid mice with inflammatory bowel disease. Eur. J. Immunol. 31 (2001) 23-31
2. Brown S.J., and Mayer L. The immune response in inflammatory bowel disease. Am. J. Gastroenterol. 102 (2007) 2058-2069
3. Cong Y., Brandwein S.L., McCabe R.P., Lazenby A., Birkenmeier E.H., Sundberg J.P., and Elson C.O. CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice. Increased T helper cell type 1 response and ability to transfer disease. J. Exp. Med. 187 (1998) 855-864
4. Cuzzocrea S., Mazzon E., Genovese T., Crisafulli C., Min W.K., Di Paola R., Muià C., Li J.H., Malleo G., Xu W., Massuda E., Esposito E., Zhang J., and Wang Z.Q. Role of poly(ADP-ribose) glycohydrolase in the development of inflammatory bowel disease in mice. Free Radic. Biol. Med. 1 42 (2007) 90-105
5. Daniel C., Sartory N., Zahn N., Geisslinger G., Radeke H.H., and Stein J.M. FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. J. Immunol. 178 (2007) 2458-2468
6. Davidson N.J., Fort M.M., MÃller W., Leach M.W., and Rennick D.M. Chronic colitis in IL-10-/- mice: insufficient counter regulation of a Th1 response. Int. Rev. Immunol. 19 1 (2000) 91-121
7. Duchmann R., Kaiser I., Hermann E., Mayet W., Ewe K., and Meyer-zum Buschenfelde K.H. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin. Exp. Immunol. 102 (1995) 448-455
8. Fantini M.C., Monteleone G., and Macdonald T.T. New players in the cytokine orchestra of inflammatory bowel disease. Inflamm. Bowel Dis. 13 (2007) 1419-1423
9. Gad M., Lundsgaard D., Kjellev S., Kristensen N.N., Seremet T., Straten P.T., and Claesson M.H. Reactivity of naive CD4+CD25- T cells against gut microflora in healthy mice. Int. Immunol. 18 (2006) 817-825
10. Gordon J.N., Di Sabatino A., and Macdonald T.T. The pathophysiologic rationale for biological therapies in inflammatory bowel disease. Curr. Opin. Gastroenterol. 21 (2005) 431-437
11. Goyette P., Labbè C., Trinh T.T., Xavier R.J., and Rioux J.D. Molecular pathogenesis of inflammatory bowel disease: genotypes, phenotypes and personalized medicine. Ann. Med. 39 (2007) 177-199
12. Groux H., and Powrie F. Regulatory T cells and inflammatory bowel disease. Immunol. Today 20 (1999) 442-445
13. Hans W., Schölmerich J., Gross V., and Falk W. The role of resident intestinal flora in acute and chronic dextran sulfate sodium-induced colitis in mice. Eur. J. Gastroenterol. Hepatol. 12 (2000) 267-273
14. Hoffmann J.C., Pawlowski N.N., Kühl A.A., Höhne W., and Zeitz M. Animal models of inflammatory bowel disease: an overview. Pathobiology 70 (2002-2003) 121-130
15. Irving P.M., Gearry R.B., Sparrow M.P., and Gibson P.R. Review article: appropriate use of corticosteroids in Crohn's disease. Aliment. Pharmacol. Ther. 26 (2007) 313-329
16. Leach M.W., Davidson N.J., Fort M.M., Powrie F., and Rennick D.M. The role of IL-10 in inflammatory bowel disease: "of mice and men". Toxicol. Pathol. 27 (1999) 123-133
17. Li M.C., and He S.H. IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J. Gastroenterol. 10 5 (2004) 620-625
18. MacDonald T.T., Monteleone G., and Pender S.L.F. Recent developments in the immunology of inflammatory bowel disease. Scand. J. Immunol. 51 (2000) 2-9
19. Neurath M.F., Pettersson S., Meyer zum Buschenfelde K.H., and Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat. Med. 2 (1996) 998-1004
20. Palmen M.J.H.J., Dieleman L., Soesatyo M., Pena A.S., Meuwissen S.G.M., and van Rees E.P. Effects of local budesonide treatment on the T cell-mediated immune response in acute and relapsing colitis in rats. Dig. Dis. Sci. 43 (1998) 2518-2523
21. Rogler G., Brand K., Vogl D., Page S., Hofmeister R., Andus T., Knuechel R., Baeuerle P.A., Scholmerich J., and Gross V. Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115 (1998) 357-369
22. Savage D.C. Mucosal microbiota. In: Ogra P.L., Mestecky J., Lamm M.E., Strober W., Bienenstock J., McGhee J.R., 1998. eds. Mucosal Immunology. San Diego: Academic Press, 1999: (19-30.Gut.);42:477-484.
23. Schreiber S., Nikolaus S., and Hampe J. Activation of nuclear factor κB inflammatory bowel disease. Gut. Oct. 43 4 (1998) 587-588
24. Stojanovic I., Cuzzocrea S., Mangano K., Mazzon E., Miljkovic D., Wang M., Donia M., Al Abed Y., Kim J., Nicoletti F., Stosic-Grujicic S., and Claesson M. In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. Clin. Immunol. 123 (2007) 311-323
25. Stosic-Grujicic S., Cvetkovic I., Mangano K., Fresta M., Maksimovic-Ivanic D., Harhaji L., Popadic D., Momcilovic M., Miljkovic D., Kim J., Al-Abed Y., and Nicoletti F. A potent immunomodulatory compound, (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of streptozotocin in CBA/H mice. J. Pharmacol. Exp. Ther. Mar. 320 3 (2007) 1038-1049
26. Wallace J.L. Glucocorticoid-induced gastric mucosal damage: inhibition of leukotriene but not prostaglandin biosynthesis. Prostaglandins 34 (1987) 311-323
27. Xavier R.J., and Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448 (2007) 427-434